nach oben

NeuroMolecular Medicine

Erschienen in:

01.12.2008 | Review Paper

Mitochondrial Medicine for Aging and Neurodegenerative Diseases

verfasst von: P. Hemachandra Reddy

Erschienen in: NeuroMolecular Medicine | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Mitochondria are key cytoplasmic organelles, responsible for generating cellular energy, regulating intracellular calcium levels, altering the reduction-oxidation potential of cells, and regulating cell death. Increasing evidence suggests that mitochondria play a central role in aging and in neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, and Freidriech ataxia. Further, several lines of evidence suggest that mitochondrial dysfunction is an early event in most late-onset neurodegenerative diseases. Biochemical and animal model studies of inherited neurodegenerative diseases have revealed that mutant proteins of these diseases are associated with mitochondria. Mutant proteins are reported to block the transport of nuclear-encoded mitochondrial proteins to mitochondria, interact with mitochondrial proteins and disrupt the electron transport chain, induce free radicals, cause mitochondrial dysfunction, and, ultimately, damage neurons. This article discusses critical issues of mitochondria causing dysfunction in aging and neurodegenerative diseases, and discusses the potential of developing mitochondrial medicine, particularly mitochondrially targeted antioxidants, to treat aging and neurodegenerative diseases.

Abe, Y., Hashimoto, Y., Tomita, Y., Terashita, K., Aiso, S., Tajima, H., et al. (2004). Cytotoxic mechanisms by M239 V presenilin 2, a little-analyzed Alzheimer’s disease-causative mutant. Journal of Neuroscience Research, 77, 583–595. doi:10.1002/jnr.20163.PubMed

Abeliovich, A., & Beal, M. F. (2006). Parkinsonism genes: Culprits and clues. Journal of Neurochemistry, 99, 1062–1072. doi:10.1111/j.1471-4159.2006.04102.x.PubMed

Afifi, A. K., Aleu, F. P., Goodgold, J., & MacKay, B. (1966). Ultrastructure of atrophic muscle in amyotrophic lateral sclerosis. Neurology, 16, 475–481.PubMed

Anandatheerthavarada, H. K., Biswas, G., Robin, M. A., & Avadhani, N. G. (2003). Mitochondrial targeting and a novel transmembrane arrest of Alzheimer’s amyloid precursor protein impairs mitochondrial function in neuronal cells. Journal of Cell Biology, 161, 41–54. doi:10.1083/jcb.200207030.PubMed

Andersen, J. K. (2004). Iron dysregulation and Parkinson’s disease. Journal of Alzheimer’s Disease, 6, S47–S52.PubMed

Anderson, S., Bankier, A. T., Barrell, B. G., de Bruijn, M. H., Coulson, A. R., Drouin, J., et al. (1981). Sequence and organization of the human mitochondrial genome. Nature, 290, 457–465. doi:10.1038/290457a0.PubMed

Anekonda, T. (2006). Resveratrol––a boon for treating Alzheimer’s disease? Brain Research Reviews, 52, 316–326. doi:10.1016/j.brainresrev.2006.04.004.PubMed

Anekonda, T. S., & Reddy, P. H. (2006). Neuronal protection by sirtuins in Alzheimer’s disease. Journal of Neurochemistry, 96, 305–313. doi:10.1111/j.1471-4159.2005.03492.x.PubMed

Ankarcrona, M., & Hultenby, K. (2002). Presenilin-1 is located in rat mitochondria. Biochemical and Biophysical Research Communications, 295, 766–770. doi:10.1016/S0006-291X(02)00735-0.PubMed

Barsoum, M. J., Yuan, H., Gerencser, A. A., et al. (2006). Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons. EMBO Journal, 25, 3900–3911. doi:10.1038/sj.emboj.7601253.PubMed

Bates, G. P. (2005). History of genetic disease: The molecular genetics of Huntington disease––a history. Nature Reviews. Genetics, 6, 766–773. doi:10.1038/nrg1686.PubMed

Beal, M. F. (2005). Mitochondria take center stage in aging and neurodegeneration. Annals of Neurology, 58, 495–505. doi:10.1002/ana.20624.PubMed

Behbahani, H., Shabalina, I. G., Wiehager, B., et al. (2006). Differential role of Presenilin-1 and -2 on mitochondrial membrane potential and oxygen consumption in mouse embryonic fibroblasts. Journal of Neuroscience Research, 84, 891–902. doi:10.1002/jnr.20990.PubMed

Beilina, A., Van Der Brug, M., Ahmad, R., Kesavapany, S., Miller, D. W., Petsko, G. A., et al. (2005). Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proceedings of the National Academy of Sciences of the United States of America, 102, 5703–5708. doi:10.1073/pnas.0500617102.PubMed

Benard, G., Bellance, N., James, D., Parrone, P., Fernandez, H., Letellier, T., et al. (2007). Mitochondrial bioenergetics and structural network organization. Journal of Cell Science, 120, 838–848. doi:10.1242/jcs.03381.PubMed

Bergemalm, D., Jonsson, P. A., Graffmo, K. S., Andersen, P. M., Brannstrom, T., Rehnmark, A., et al. (2006). Overloading of stable and exclusion of unstable human superoxide dismutase-1 variants in mitochondria of murine amyotrophic lateral sclerosis models. Journal of Neuroscience, 26, 4147–4154. doi:10.1523/JNEUROSCI.5461-05.2006.PubMed

Blander, G., & Guarente, L. (2004). The Sir2 family of protein deacetylases. Annual Review of Biochemistry, 73, 417–435. doi:10.1146/annurev.biochem.73.011303.073651.PubMed

Boillee, S., Vande Velde, C., & Cleveland, D. W. (2006). ALS: A disease of motor neurons and their nonneuronal neighbors. Neuron, 52, 39–59. doi:10.1016/j.neuron.2006.09.018.PubMed

Bonifati, V., Rizzu, P., van Baren, M. J., et al. (2003). Mutations in the DJ-1 gene associated with autosomal recessive early-onset Parkinsonism. Science, 299, 256–259. doi:10.1126/science.1077209.PubMed

Bossy-Wetzel, E., Barsoum, M. J., Godzik, A., Schwarzenbacher, R., & Lipton, S. A. (2003). Mitochondrial fission in apoptosis, neurodegeneration and aging. Current Opinion in Cell Biology, 15, 706–716. doi:10.1016/j.ceb.2003.10.015.PubMed

Boyd-Kimball, D., Sultana, R., Abdul, H. M., & Butterfield, D. A. (2005a). Gamma-glutamylcysteine ethyl ester-induced up-regulation of glutathione protects neurons against Abeta(1–42)-mediated oxidative stress and neurotoxicity: Implications for Alzheimer’s disease. Journal of Neuroscience Research, 79, 700–706. doi:10.1002/jnr.20394.PubMed

Boyd-Kimball, D., Sultana, R., Poon, H. F., Mohmmad-Abdul, H., Lynn, B. C., Klein, J. B., et al. (2005b). Gamma-glutamylcysteine ethyl ester protection of proteins from Abeta(1-42)-mediated oxidative stress in neuronal cell culture: A proteomics approach. Journal of Neuroscience Research, 79, 707–713. doi:10.1002/jnr.20393.PubMed

Bozner, P., Grishko, V., LeDoux, S. P., Wilson, G. L., Chyan, Y. C., & Pappolla, M. A. (1997). The amyloid beta protein induces oxidative damage of mitochondrial DNA. Journal of Neuropathology and Experimental Neurology, 56, 1356–1362. doi:10.1097/00005072-199712000-00010.PubMed

Browne, S. E., & Beal, M. F. (2004). The energetics of Huntington’s disease. Neurochemical Research, 29, 531–546. doi:10.1023/B:NERE.0000014824.04728.dd.PubMed

Browne, S. E., & Beal, M. F. (2006). Oxidative damage in Huntington’s disease pathogenesis. Antioxidants Redox Signaling, 8, 2061–2073. doi:10.1089/ars.2006.8.2061.PubMed

Browne, S. E., Bowling, A. C., MacGarvey, U., Baik, M. J., Berger, S. C., Muqit, M. M., et al. (1997). Oxidative damage and metabolic dysfunction in Huntington’s disease: Selective vulnerability of the basal ganglia. Annals of Neurology, 41, 646–653. doi:10.1002/ana.410410514.PubMed

Bruijn, L. I., Houseweart, M. K., Kato, S., Anderson, K. L., Anderson, S. D., Ohama, E., et al. (1998). Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science, 281, 1851–1854. doi:10.1126/science.281.5384.1851.PubMed

Campuzano, V., Montermini, L., Molto, M. D., et al. (1996). Friedreich’s ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science, 271, 1423–1427. doi:10.1126/science.271.5254.1423.PubMed

Canet-Avilés, R. M., Wilson, M. A., Miller, D. W., Ahmad, R., McLendon, C., Bandyopadhyay, S., et al. (2004). The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proceedings of the National Academy of Sciences of the United States of America, 101, 9103–9108.PubMed

Caspersen, C., Wang, N., Yao, J., Sosunov, A., Chen, X., Lustbader, J. W., et al. (2005). Mitochondrial Abeta: A potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. FASEB Journal, 19, 2040–2041.PubMed

Chan, D. C. (2006). Mitochondrial fusion and fission in mammals. Annual Review of Cell and Developmental Biology, 22, 79–99. doi:10.1146/annurev.cellbio.22.010305.104638.PubMed

Chan, S. L., Furukawa, K., & Mattson, M. P. (2002). Presenilins and APP in neuritic and synaptic plasticity: Implications for the pathogenesis of Alzheimer’s disease. Neuromolecular Medicine, 2, 167–196. doi:10.1385/NMM:2:2:167.PubMed

Chang, S., Ran, M. A. T., Miranda, R. D., Balestra, M. E., Mahley, R. W., & Huang, Y. (2005). Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 102, 18694–18689 doi:10.1073/pnas.0508254102.

Chang, D. T., & Reynolds, I. J. (2006). Mitochondrial trafficking and morphology in healthy and injured neurons. Progress in Neurobiology, 80, 241–268. doi:10.1016/j.pneurobio.2006.09.003.PubMed

Chang, D. T., Rintoul, G. L., Pandipati, S., & Reynolds, I. J. (2006). Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiology of Disease, 22, 388–400. doi:10.1016/j.nbd.2005.12.007.PubMed

Chen, X., Liang, H., Van Remmen, H., Vijg, J., & Richradson, A. (2004). Catalase transgenic mice: Characterization and sensitivity to oxidative stress. Archives of Biochemistry and Biophysics, 422, 197–210. doi:10.1016/j.abb.2003.12.023.PubMed

Cho, S., Szeto, H. H., Kim, E., Kim, H., Tolhurst, A. T., & Pinto, J. T. (2007a). A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. Journal of Biological Chemistry, 282, 4634–4642. doi:10.1074/jbc.M609388200.PubMed

Cho, J., Won, K., Wu, D., Soong, Y., Liu, S., Szeto, H. H., et al. (2007b). Potent mitochondria-targeted peptides reduce myocardial infarction in rats. Coronary Artery Disease, 18, 215–220. doi:10.1097/01.mca.0000236285.71683.b6.PubMed

Chung, M. J., & Suh, Y. L. (2002). Ultrastructural changes of mitochondria in the skeletal muscle of patients with amyotrophic lateral sclerosis. Ultrastructural Pathology, 26, 3–7. doi:10.1080/01913120252934260.PubMed

Cocheme, H. M., Kelso, G. F., James, A. M. Ross, M. F., Trnka, J., Mahendrian, T., Asin-Cayuela, J., Blaike, F. H., Manas, A. R., Porteous, C. M., Adlam, V. J., Smith, R. A. & Murphy, M. P. (2007). Mitochondrial targeting of quinones: Therapeutic implications. Mitochondrion (Suppl:S94–S102) doi:10.1016/j.mito.2007.02.007.

Cooper, J. M., Mann, V. M., & Schapira, A. H. (1992). Analyses of mitochondrial respiratory chain function and mitochondrial DNA deletion in human skeletal muscle: Effect of ageing. Journal of the Neurological Sciences, 113, 91–98. doi:10.1016/0022-510X(92)90270-U.PubMed

Copeland, W. C. (2008). Inherited mitochondrial diseases of DNA replication. Annual Review of Medicine, 59, 131–146. doi:10.1146/annurev.med.59.053006.104646.PubMed

Corral-Debrinski, M., Horton, T., Lott, M. T., Shoffner, J. M., McKee, A. C., Beal, M. F., et al. (1994). Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. Genomics, 23, 471–476. doi:10.1006/geno.1994.1525.PubMed

Crouch, P. J., Blake, R., Duce, J. A., et al. (2005). Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1–42. Journal of Neuroscience, 25, 672–679. doi:10.1523/JNEUROSCI.4276-04.2005.PubMed

Cui, L., Jeong, H., Borovecki, F., Parkhurst, C. N., Tanese, N., & Krainc, D. (2006). Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell, 127, 59–69. doi:10.1016/j.cell.2006.09.015.PubMed

Deng, H. X., Shi, Y., Furukawa, Y., Zhai, H., et al. (2006). Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proceedings of the National Academy of Sciences of the United States of America, 103, 7142–7147. doi:10.1073/pnas.0602046103.PubMed

Derossi, D., Calvet, S., Trembleau, A., Brunissen, A., Chassaing, G., & Prochiantz, A. (1996). Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. Journal of Biological Chemistry, 271, 18188–18193. doi:10.1074/jbc.271.30.18188.PubMed

Devi, L., Prabhu, B. M., Galati, D. F., Avadhani, N. G., & Anandatheerthavarada, H. K. (2006). Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer’s disease brain is associated with mitochondrial dysfunction. Journal of Neuroscience, 26, 9057–9068. doi:10.1523/JNEUROSCI.1469-06.2006.PubMed

Devi, L., Raghavendran, V., Prabhu, B. M., Avadhani, N. G., & Anandatheerthavarada, H. K. (2008). Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. Journal of Biological Chemistry, 283, 9089–9100. doi:10.1074/jbc.M710012200.PubMed

Dhanasekaran, A., Kotamraju, S., Kalivendi, S. V., Matsunaga, T., Shang, T., Keszler, A., Jpseph, J., & Kalyanaraman, B. (2004). Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. Jounal of Biological Chemistry, 279, 37575–37587.

Ding, Q., Cecarini, V., & Keller, J. N. (2007). Interplay between protein synthesis and degradation in the CNS: Physiological and pathological implications. Trends in Neurosciences, 30, 31–36. doi:10.1016/j.tins.2006.11.003.PubMed

Drin, G., Cottin, S., Blanc, E., Rees, A. R., & Temsamani, J. (2003). Studies on the internalization mechanism of cationic cell-penetrating peptides. Journal of Biological Chemistry, 278, 31192–31201. doi:10.1074/jbc.M303938200.PubMed

Dupuis, L., di Scala, F., Rene, F., de Tapia, M., Oudart, H., Pradat, P. F., et al. (2003). Up-regulation of mitochondrial uncoupling protein 3 reveals an early muscular metabolic defect in amyotrophic lateral sclerosis. FASEB Journal, 17, 2091–2093.PubMed

Farrer, M., Stone, J., Mata, I. F., Lincoln, S., Kachergus, J., Hulihan, M., et al. (2005). LRRK2 mutations in Parkinson disease. Neurology, 65, 738–740. doi:10.1212/01.WNL.0000169023.51764.b0.PubMed

Fromenty, B., Grimbert, S., Mansouri, A., Beaugrand, M., Erlinger, S., Rotug, A., et al. (1995). Hepatic mitochondrial DNA deletion in alcoholics: Association with microvesicular steatosis. Gastroenterology, 108, 193–200. doi:10.1016/0016-5085(95)90024-1.PubMed

Folstein, S. E. (1990). Huntington’s Disease. Baltimore: Johns Hopkins University Press.

Fukui, H., & Moraes, C. T. (2007). Extended polyglutamine repeats trigger a feedback loop involving the mitochondrial complex III, the proteasome and huntingtin aggregates. Human Molecular Genetics, 16, 783–797. doi:10.1093/hmg/ddm023.PubMed

Furukawa, Y., Fu, R., Deng, H. X., Siddique, T., & O’Halloran, T. V. (2006). Disulfide cross-linked protein represents a significant fraction of ALS-associated Cu, Zn-superoxide dismutase aggregates in spinal cords of model mice. Proceedings of the National Academy of Sciences of the United States of America, 103, 7148–7153. doi:10.1073/pnas.0602048103.PubMed

Galluzzi, L., Larochette, N., Zamzami, N., & Kroemer, G. (2006). Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene, 25, 4812–4830. doi:10.1038/sj.onc.1209598.PubMed

Galter, D., Westerlund, M., Carmine, A., Lindqvist, E., Sydow, O., & Olson, L. (2006). LRRK2 expression linked to dopamine-innervated areas. Annals of Neurology, 59, 714–719. doi:10.1002/ana.20808.PubMed

Gandhi, S., & Wood, N. W. (2005). Molecular pathogenesis of Parkinson’s disease. Human Molecular Genetics, 14, 2749–2755.

Gibson, G. E., Sheu, K. F., & Blass, J. P. (1998). Abnormalities of mitochondrial enzymes in Alzheimer disease. Journal of Neural Transmission, 105, 855–870. doi:10.1007/s007020050099.PubMed

Gilks, W. P., Abou-Sleiman, P. M., Gandhi, S., Jain, S., et al. (2005). A common LRRK2 mutation in idiopathic Parkinson’s disease. Lancet, 365, 415–416.PubMed

Guarente, L. (2000). Sir2 links chromatin silencing, metabolism, and aging. Genes and Development, 14, 1021–1026.PubMed

Guo, Q., Sebastian, L., Sopher, B. L., Miller, M. W., Ware, C. B., Martin, G. M., et al. (1999). Increased vulnerability of hippocampal neurons from presenilin-1 mutant knock-in mice to amyloid beta-peptide toxicity: Central roles of superoxide production and caspase activation. Journal of Neurochemistry, 72, 1019–1029. doi:10.1046/j.1471-4159.1999.0721019.x.PubMed

Guo, Q., Sopher, B. L., Furukawa, K., Pham, D. G., Robinson, N., Martin, G. M., et al. (1997). Alzheimer’s presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta-peptide: Involvement of calcium and oxyradicals. Journal of Neuroscience, 17, 4212–4222.PubMed

Gurney, M. E., Pu, H., Chiu, A. Y., et al. (1994). Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science, 264, 1772–1775. doi:10.1126/science.8209258.PubMed

Hansson, C. A., Frykman, S., Farmery, M. R., et al. (2004). Nicastrin, presenilin, APH-1, and PEN-2 form active gamma-secretase complexes in mitochondria. Journal of Biological Chemistry, 279, 51654–51660. doi:10.1074/jbc.M404500200.PubMed

Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science, 297, 353–356. doi:10.1126/science.1072994.PubMed

Hausse, A. O., Aggoun, Y., Bonnet, D., Sidi, D., Munnich, A., Rotig, A., et al. (2002). Idebenone and reduced cardiac hypertrophy in Friedreich’s ataxia. Heart, 87, 346–349. doi:10.1136/heart.87.4.346.PubMed

Hervias, I., Beal, M. F., & Manfredi, G. (2006). Mitochondrial dysfunction and amyotrophic lateral sclerosis. Muscle and Nerve, 33, 598–608. doi:10.1002/mus.20489.PubMed

Higgins, C. M., Jung, C., & Xu, Z. (2003). ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neuroscience, 4, 16. doi:10.1186/1471-2202-4-16.PubMed

Hirai, K., Aliev, G., Nunomura, A., et al. (2001). Mitochondrial abnormalities in Alzheimer’s disease. Journal of Neuroscience, 21, 3017–3023.PubMed

Hirano, A., Donnenfeld, H., Sasaki, S., & Nakano, I. (1984). Fine structural observations of neurofilamentous changes in amyotrophic lateral sclerosis. Journal of Neuropathology and Experimental Neurology, 43, 461–470. doi:10.1097/00005072-198409000-00001.PubMed

Hodgson, J. G., Agopyan, N., Gutekunst, C. A., et al. (1999). A YAC mouse model for Huntington’s disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron, 23, 181–192. doi:10.1016/S0896-6273(00)80764-3.PubMed

Horton, T. M., Graham, B. H., Corral-Debranski, M., Shoffner, J. M., Kaufman, A. E., Beal, M. F., et al. (1995). Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington’s disease patients. Neurology, 45, 1879–1883.PubMed

Howell, N., Elson, J. L., Chinnery, P. F., & Turnbull, D. M. (2005). mtDNA mutations and common neurodegenerative disorders. Trends in Genetics, 21, 583–586. doi:10.1016/j.tig.2005.08.012.PubMed

Huang, C. C., Faber, P. W., Persichetti, F., Mittal, V., Vonsattel, J. P., MacDonald, M. E., et al. (1998). Amyloid formation by mutant huntingtin: Threshold, progressivity and recruitment of normal polyglutamine proteins. Somatic Cell and Molecular Genetics, 24, 217–233. doi:10.1023/B:SCAM.0000007124.19463.e5.PubMed

Ikebe, S., Tanaka, M., Ohno, K., Sato, W., Hattori, K., Kondo, T., et al. (1990). Increase of deleted mitochondrial DNA in the striatum in Parkinson’s disease and senescence. Biochemical and Biophysical Research Communications, 170, 1044–1048. doi:10.1016/0006-291X(90)90497-B.PubMed

Jauslin, M. L., Meier, T., Smith, R. A., & Murphy, M. P. (2003). Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB Journal, 17(13), 1972–1974.PubMed

Jin, J., Meredeith, G. E., Chen, L., Zhou, Y., Xu, J., Shie, F. S., Lockhart, P., & Zhang, J. (2005). Quantitative proteomic analysis of mitochondrial proteins: Relevance to Lewy body formation and Parkinson's disease. Brain Research. Molecular Brain Research, 134, 119–138.PubMed

Jonsson, P. A., Graffmo, K. S., Andersen, P. M., Brannstrom, T., Lindberg, M., Oliveberg, M., et al. (2006). Disulphide-reduced superoxide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models. Brain, 129, 451–464. doi:10.1093/brain/awh704.PubMed

Kao, S., Chao, H. T., & Wei, Y. H. (1995). Mitochondrial deoxyribonucleic acid 4977-bp deletion is associated with diminished fertility and motility of human sperm. Biology of Reproduction, 52, 729–736. doi:10.1095/biolreprod52.4.729.PubMed

Keller, J. N., Guo, Q., Holtsberg, F. W., Bruce-Keller, A. J., & Mattson, M. P. (1998). Increased sensitivity to mitochondrial toxin-induced apoptosis in neural cells expressing mutant presenilin-1 is linked to perturbed calcium homeostasis and enhanced oxyradical production. Journal of Neuroscience, 18, 4439–4450.PubMed

Khan, S. M., Cassarino, D. S., Abramova, N. N., Keeney, P. M., Borland, M. K., Timmer, P. A., et al. (2000). Alzheimer’s disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Annals of Neurology, 48, 148–155. doi:10.1002/1531-8249(200008)48:2<148::AID-ANA3>3.0.CO;2-7.

Kim, D., Nguyen, M. D., Dobbin, M. M., Fischer, A., Sananbenesi, F., Rodgers, J. T., et al. (2007). SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis. EMBO Journal, 26, 3169–3179. doi:10.1038/sj.emboj.7601758.PubMed

Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., et al. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 392, 605–608. doi:10.1038/33416.PubMed

Kotake, Y. (1999). Pharmacologic properties of phenyl N-tert-butylnitrone. Antioxidants Redox Signaling, 1, 481–499.PubMed

Kroemer, G. (2006). Mitochondria in cancer. Oncogene, 25, 4630–4632. doi:10.1038/sj.onc.1209589.PubMed

Kujoth, G. C., Hiona, A., Pugh, T. D., et al. (2005). Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science, 309, 481–448. doi:10.1126/science.1112125.PubMed

Kujoth, G. C., Leeuwenburgh, C., & Prolla, T. A. (2006). Mitochondrial DNA mutations and apoptosis in mammalian aging. Cancer Research, 66, 7386–7389. doi:10.1158/0008-5472.CAN-05-4670.PubMed

Kwong, J. Q., Beal, M. F., & Manfredi, G. (2006). The role of mitochondria in inherited neurodegenerative diseases. Journal of Neurochemistry, 97, 1659–1675. doi:10.1111/j.1471-4159.2006.03990.x.PubMed

LaFerla, F. M., Gree, K. N., & Oddo, S. (2007). Intracellular amyloid-beta in Alzheimer’s disease. Nature Reviews. Neuroscience, 8, 499–509. doi:10.1038/nrn2168.PubMed

Lamming, D. W., Wood, J. G., & Sinclair, D. A. (2004). Small molecules that regulate lifespan: Evidence for xenohormesis. Molecular Microbiology, 53, 1003–1009. doi:10.1111/j.1365-2958.2004.04209.x.PubMed

Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983). Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 219, 979–980. doi:10.1126/science.6823561.PubMed

Leroy, E., Boyer, R., Auburger, G., et al. (1998). The ubiquitin pathway in Parkinson’s disease. Nature, 395, 451–452. doi:10.1038/26652.PubMed

Li, F., Calingasan, N. Y., Yu, F., et al. (2004). Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. Journal of Neurochemistry, 89, 1308–1312. doi:10.1111/j.1471-4159.2004.02455.x.PubMed

Li, S., & Li, X. J. (2006). Multiple pathways contribute to the pathogenesis of Huntington disease. Molecular Neurodegeneration, 1, 19. doi:10.1186/1750-1326-1-19.PubMed

Liang, H., & Ward, W. F. (2006). PGC-1alpha: A key regulator of energy metabolism. Advances in Physiology Education, 30(4), 145–151. doi:10.1152/advan.00052.2006.PubMed

Lin, M. T., & Beal, M. F. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 443, 787–795. doi:10.1038/nature05292.PubMed

Liu, J., Lillo, C., Jonsson, P. A., et al. (2004). Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron, 43, 5–17. doi:10.1016/j.neuron.2004.06.016.PubMed

Lustbader, J. W., Cirilli, M., Lin, C., et al. (2004). ABAD directly links Abeta to mitochondrial toxicity in Alzheimer’s disease. Science, 304, 448–452. doi:10.1126/science.1091230.PubMed

Manczak, M., Anekonda, T. S., Henson, E., Park, B. S., Quinn, J., & Reddy, P. H. (2006). Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: Implications for free radical generation and oxidative damage in disease progression. Human Molecular Genetics, 15, 1437–1449. doi:10.1093/hmg/ddl066.PubMed

Manczak, M., Park, B. S., Jung, Y., & Reddy, P. H. (2004). Differential expression of oxidative phosphorylation genes in patients with Alzheimer’s disease: Implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Medicine, 5, 147–162. doi:10.1385/NMM:5:2:147.PubMed

Mandelkow, E. M., Thies, E., Trinczek, B., Biernat, J., & Mandelkow, E. (2004). MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. Journal of Cell Biology, 167, 99–110. doi:10.1083/jcb.200401085.PubMed

Martin, L. J. (2006). Mitochondriopathy in Parkinson disease and amyotrophic lateral sclerosis. Journal of Neuropathology and Experimental Neurology, 65, 1103–1110. doi:10.1097/01.jnen.0000248541.05552.c4.PubMed

Mattson, M. P. (2004). Pathways towards and away from Alzheimer’s disease. Nature, 430, 631–639. doi:10.1038/nature02621.PubMed

Mattson, M. P. (2007). Calcium and neurodegeneration. Aging Cell, 6, 337–350. doi:10.1111/j.1474-9726.2007.00275.x.PubMed

Maurer, I., Zierz, S., & Moller, H. J. (2000). A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiology of Aging, 21, 455–462. doi:10.1016/S0197-4580(00)00112-3.PubMed

Mohmmad Abdul, H., Sultana, R., Keller, J. N., St Clair, D. K., Markesbery, W. R., & Butterfield, D. A. (2006). Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1–42), HO and kainic acid: Implications for Alzheimer’s disease. Journal of Neurochemistry, 96, 1322–1335. doi:10.1111/j.1471-4159.2005.03647.x.PubMed

Moreira, P. I., Santos, M. S., Seica, R., & Oliveira, C. R. (2007). Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. Journal of the Neurological Sciences, 257, 206–214. doi:10.1016/j.jns.2007.01.017.

Murphy, M. P., Echtay, K. S., Blaikie, F. H., et al. (2003). Superoxide activates uncoupling proteins by generating carbon-centered radicals and initiating lipid peroxidation: Studies using a mitochondria-targeted spin trap derived from alpha-phenyl-N-tert-butylnitrone. Journal of Biological Chemistry, 278, 48534–48545. doi:10.1074/jbc.M308529200.PubMed

Murphy, M. P., & Smith, R. A. (2007). Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annual Review of Pharmacology and Toxicology, 47, 629–656. doi:10.1146/annurev.pharmtox.47.120505.105110.PubMed

Nichols, W. C., Pankratz, N., Hernandez, D., Paisan-Ruiz, C., et al. (2005). Genetic screening for a single common LRRK2 mutation in familial Parkinson’s disease. Lancet, 365, 410–412.PubMed

Nunomura, A., Castellani, R. J., Zhu, X., Moreira, P. I., Perry, G., & Smith, M. A. (2006). Involvement of oxidative stress in Alzheimer disease. Journal of Neuropathology and Experimental Neurology, 65, 631–641. doi:10.1097/01.jnen.0000228136.58062.bf.PubMed

Orr, A. L., Li, S., Wang, C. E., Wang, J., Rong, J., Xu, X., et al. (2008). N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. Journal of Neuroscience, 28, 2783–2792. doi:10.1523/JNEUROSCI.0106-08.2008.PubMed

Ozawa, T., Tanaka, M., Ikebe, S., Ohno, K., Kondo, T., & Mizuno, Y. (1990). Quantitative determination of deleted mitochondrial DNA relative to normal DNA in parkinsonian striatum by a kinetic PCR analysis. Biochemical and Biophysical Research Communications, 172, 483–489. doi:10.1016/0006-291X(90)90698-M.PubMed

Paisan-Ruiz, C., Jain, S., Evans, E. W., Gilks, W. P., et al. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron, 44, 595–600. doi:10.1016/j.neuron.2004.10.023.PubMed

Panov, A. V., Gutekunst, C. A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., et al. (2002). Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamines. Nature Neuroscience, 5, 731–736.PubMed

Panov, A. V., Lund, S., & Greenamyre, J. T. (2005). Ca2 + -induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington’s disease individuals. Molecular and Cellular Biochemistry, 269, 143–152. doi:10.1007/s11010-005-3454-9.PubMed

Parker, J. A., Arango, M., Abderrahmane, S., Lambert, E., Tourette, C., Catoire, H., et al. (2005). Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nature Genetics, 37, 349–350. doi:10.1038/ng1534.PubMed

Parker, W. D., Jr., Boyson, S. J., & Parks, J. K. (1989). Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Annals of Neurology, 26, 719–723. doi:10.1002/ana.410260606.PubMed

Parker, W. D., Jr., Filley, C. M., & Parks, J. K. (1990). Cytochrome oxidase deficiency in Alzheimer’s disease. Neurology, 40, 1302–1303.PubMed

Patel, N. V., Gordon, M. N., Connor, K. E., Good, R. A., Engelmann, R. W., Mason, J., Morgan, D. G., Morgan, T. E., & Finch, C. E. (2005). Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiology of Aging, 26, 995–1000.PubMed

Perez, M. K., Paulson, H. L., Pendse, S. J., Saionz, S. J., Bonini, N. M., & Pittman, R. N. (1998). Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. Journal of Cell Biology, 143, 1457–1470. doi:10.1083/jcb.143.6.1457.PubMed

Perry, G., Roder, H., Nunomura, A., et al. (1999). Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. NeuroReport, 10, 2411–4215.PubMed

Petri, S., Kiaei, M., Damiano, M., Hiller, A., Wille, E., Manfredi, G., Calingasan, N. Y., Szeto, H. H., & Beal, M. F. (2006). Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry, 98, 1141–1148.

Pocernich, C. B., Cardin, A. L., Racine, C. L., Lauderback, C. M., & Butterfield, D. A. (2001). Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: Relevance to brain lipid peroxidation in neurodegenerative disease. Neurochemistry International, 39, 141–149. doi:10.1016/S0197-0186(01)00012-2.PubMed

Polymeropoulos, M. H., Lavedan, C., Leroy, E., et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science, 276, 2045–2047. doi:10.1126/science.276.5321.2045.PubMed

Qin, W., Chachich, M., Lane, M., et al. (2006a). Calorie restriction attenuates Alzheimer’s disease type brain amyloidosis in Squirrel monkeys (Saimiri sciureus). Journal of Alzheimer’s Disease, 10, 417–422.PubMed

Qin, W., Yang, T., Ho, L., et al. (2006b). Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. Journal of Biological Chemistry, 281, 21745–21754. doi:10.1074/jbc.M602909200.PubMed

Rabol, R., Boushel, R., & Dela, F. (2006). Mitochondrial oxidative function and type 2 diabetes. Applied Physiology, Nutrition, and Metabolism, 31, 675–683. doi:10.1139/H06-071.PubMed

Ran, Q., Liang, H., Gu, M., Qi, W., Walter, C. A., Roberts, L. J., et al. (2004). Transgenic mice overexpressing glutathione peroxidase 4 are protected against oxidative stress-induced apoptosis. Journal of Biological Chemistry, 279, 55137–55146. doi:10.1074/jbc.M410387200.PubMed

Reddy, P. H. (2006a). Amyloid precursor protein-mediated free radicals and oxidative damage: Implications for the development and progression of Alzheimer’s disease. Journal of Neurochemistry, 96, 1–13. doi:10.1111/j.1471-4159.2005.03530.x.PubMed

Reddy, P. H. (2006b). Mitochondrial oxidative damage in aging and Alzheimer’s disease: Implications for mitochondrially targeted antioxidant therapeutics. Journal of Biomedicine & Biotechnology, 31372, 13.

Reddy, P. H. (2007). Mitochondrial dysfunction in aging and Alzheimer’s disease: Strategies to protect neurons. Antioxidants Redox Signaling, 9, 1647–1658. doi:10.1089/ars.2007.1754.PubMed

Reddy, P. H., & Beal, M. F. (2005). Are mitochondria critical in the pathogenesis of Alzheimer’s disease? Brain Research. Brain Research Reviews, 49, 618–632. doi:10.1016/j.brainresrev.2005.03.004.PubMed

Reddy, P. H., & Beal, M. F. (2008). Amyloid beta, mitochondrial dysfunction, and synaptic damage: Implications for cognitive decline in aging and Alzheimer’s disease. Trends in Molecular Medicine, 14, 45–53. doi:10.1016/j.molmed.2007.12.002.PubMed

Reddy, P. H., & McWeeney, S. (2006). Mapping cellular transcriptosomes in autopsied Alzheimer’s disease subjects and relevant animal models. Neurobiology of Aging, 27, 1060–1077. doi:10.1016/j.neurobiolaging.2005.04.014.PubMed

Reddy, P. H., McWeeney, S., Park, B. S., Manczak, M., Gutala, R. V., Partovi, D., et al. (2004). Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: Up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer’s disease. Human Molecular Genetics, 13, 1225–1240. doi:10.1093/hmg/ddh140.PubMed

Reddy, P. H., & Tagle, D. A. (1999). Biology of trinucleotide repeat disorders. In P. M. Mattson (Ed.) (Vol. 3). Genetic aberrancies and neurodegenerative disorders. Advances in cell aging and gerontology. Stanford, Connecticut: Jai press Inc.

Reddy, P. H., Williams, M., Charles, V., Garrett, L., Pike-Bucanan, L., Whetsell, W. O. Jr., Miller, G., & Tagle, D. A. (1998). Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nature Genetics, 20, 198–202.

Reddy, P. H., Williams, M., & Tagle, D. A. (1999). Recent advances in understanding the pathogenesis of Huntington’s disease. Trends in Neurosciences, 22, 248–255. doi:10.1016/S0166-2236(99)01415-0.PubMed

Richter, C., Park, J. W., & Ames, B. N. (1988). Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proceedings of the National Academy of Sciences of the United States of America, 85, 6465–6467. doi:10.1073/pnas.85.17.6465.PubMed

Rogaeva, E., Meng, Y., Lee, J. H., et al. (2007). The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nature Genetics, 39, 168–177. doi:10.1038/ng1943.PubMed

Rolo, A. P., & Palmeira, C. M. (2006). Diabetes and mitochondrial function: Role of hyperglycemia and oxidative stress. Toxicology and Applied Pharmacology, 212, 167–178. doi:10.1016/j.taap.2006.01.003.PubMed

Saunders, A. M., Strittmatter, W. J., Schmechel, D., George-Hyslop, H. P., Perricak-Vance, M. A., Joo, S. H., et al. (1993). Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology, 43, 1467–1472.PubMed

Sasaki, S., Warita, H., Murakami, T., Abe, K., & Iwata, M. (2004). Ultrastructural study of mitochondria in the spinal cord of transgenic mice with a G93A mutant SOD1 gene. Acta Neuropathologica, 107, 461–474.

Sayer, J. A., Manczak, M., Akileswaran, L., Reddy, P. H., & Coghlan, V. M. (2005). Interaction of the nuclear matrix protein NAKAP with HypA and huntingtin: Implications for nuclear toxicity in Huntington’s disease pathogenesis. Neuromolecular Medicine, 7, 297–310. doi:10.1385/NMM:7:4:297.PubMed

Schapira, A. H. (2006). Mitochondrial disease. Lancet, 368, 70–82. doi:10.1016/S0140-6736(06)68970-8.PubMed

Schapira, A. H., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990). Mitochondrial complex I deficiency in Parkinson’s disease. Journal of Neurochemistry, 54, 823–827. doi:10.1111/j.1471-4159.1990.tb02325.x.PubMed

Schilling, G., Becher, M. W., Sharp, A. H., et al. (1999). Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Human Molecular Genetics, 8, 397–407. doi:10.1093/hmg/8.3.397.PubMed

Schmidt, C., Lepsverdize, E., Chi, S. L., Das, A. M., Pizzo, S. V., Dityatev, A., & Schachner, M. (2007). Amyloid precursor protein and amyloid beta-peptide bind to ATP synthase and regulate its activity at the surface of neural cells. Molecular Psychiatry [Epub ahead of print].

Schriner, S. E., Linford, N. J., Martin, G. M., et al. (2005). Extension of murine lifespan by overexpression of catalase targeted to mitochondria. Science, 308, 1909–1911. doi:10.1126/science.1106653.PubMed

Schultz, D., & Harrison, D. G. (2000). Quest for fire: Seeking the source of pathogenic oxygen radicals in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 1412–1423.PubMed

Selkoe, D. J. (2001). Alzheimer’s disease: Genes, proteins, and therapy. Physiological Reviews, 81, 741–766.PubMed

Seong, I. S., Ivanova, E., Lee, J. M., et al. (2005). HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Human Molecular Genetics, 14, 2871–2880.

Sheu, S. S., Nauduri, D., & Anders, M. W. (2006). Targeting antioxidants to mitochondria: A new therapeutic direction. Biochimica et Biophysica Acta, 1762, 256–265.PubMed

Shimohata, T., Nakajima, T., Yamada, M., et al. (2000). Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nature Genetics, 26, 29–36. doi:10.1038/79139.PubMed

Shirane, M., & Nakayama, K. I. (2003). Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. Nature Cell Biology, 5, 28–37. doi:10.1038/ncb894.PubMed

Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Agid, Y., Javoy-Agid, F., et al. (1994). Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Annals of Neurology, 36, 348–355. doi:10.1002/ana.410360305.PubMed

Siler-Marsiglio, K. I., Pan, Q., Paiva, M., Madorsky, I., Kurana, N. C., & Heato, M. B. (2005). Mitochondrially targeted vitamin E and vitamin E mitigate ethanol-mediated effects on cerebellar granule cell antioxidant defense systems. Brain Research, 1052, 202–211.PubMed

Simon, D. K., Pulst, S. M., Sutton, J. P., Browne, S. E., Beal, M. F., & John, D. R. (1999). Familial multisystem degeneration with parkinsonism associated with the 11778 mitochondrial DNA mutation. Neurology, 53, 1787–1793.PubMed

Simmons, R. A. (2006). Developmental origins of diabetes: The role of oxidative stress. Free Radical Biology and Medicine, 40, 917–922. doi:10.1016/j.freeradbiomed.2005.12.018.PubMed

Smith, M. A., Hirai, K., Hsiao, K., Pappolla, M. A., Harris, P. L., Siedlak, S. L., et al. (1998). Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. Journal of Neurochemistry, 70, 2212–2215.PubMed

Smith, M. A., Perry, G., Richey, P. L., Sayre, L. M., Anderson, V. E., Beal, M. F., et al. (1996). Oxidative damage in Alzheimer’s. Nature, 382, 120–121. doi:10.1038/382120b0.PubMed

Smith, R. A., Porteous, C. M., Coulter, C. V., & Murphy, M. P. (1999). Selective targeting of an antioxidant to mitochondria. European Journal of Biochemistry, 263, 709–716. PubMed

Stamer, K., Vogel, R., Thies, E., Mandelkow, E., & Mandelkow, E. M. (2002). Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons & enhances oxidative stress. Journal of Cell Biology, 156, 1051–1063. doi:10.1083/jcb.200108057.PubMed

St-Pierre, J., Drori, S., Uldry, M., et al. (2006). Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell, 127, 397–408. doi:10.1016/j.cell.2006.09.024.PubMed

Strauss, K. M., Martins, L. M., Plun-Favreau, H., et al. (2005). Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson’s disease. Human Molecular Genetics, 14, 2099–2111. doi:10.1093/hmg/ddi215.PubMed

Sultana, R., Perluigi, M., & Butterfield, D. A. (2006). Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer’s disease: Insights into mechanism of neurodegeneration from redox proteomics. Antioxidants Redox Signaling, 8, 2021–2037. doi:10.1089/ars.2006.8.2021.PubMed

Swerdlow, R. H. (2007a). Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies. Journal of Neuroscience Research, 85, 3416–3428. doi:10.1002/jnr.21167.PubMed

Swerdlow, R. H. (2007b). Treating neurodegeneration by modifying mitochondria: Potential solutions to a complex problem. Antioxidants Redox Signaling, 9, 1591–1603. doi:10.1089/ars.2007.1676.PubMed

Swerdlow, R. H., & Khan, S. M. (2004). A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease. Medical Hypotheses, 63, 8–20. doi:10.1016/j.mehy.2003.12.045.PubMed

Swerdlow, R. H., Parks, J. K., Cassarino, D. S., Maguire, D. J., Maguire, R. S., Bennett, J. P., Jr., et al. (1997). Cybrids in Alzheimer’s disease: A cellular model of the disease? Neurology, 49, 918–925.

Szeto, H. H. (2006a). Mitochondria-targeted peptide antioxidants: Novel neuroprotective agents. AAPS Journal, 8, E521–E531. doi:10.1208/aapsj080362.PubMed

Szeto, H. H. (2006b). Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS Journal, 8, E277–E283.PubMed

Szeto, H. H. (2008). Mitochondria-Targeted Cytoprotective Peptides for Ischemia-Reperfusion Injury. Antioxidants Redox Signaling, 10, 601–620. doi: 10.1089/ars.2007.1892.PubMed

Szeto, H. H., Lovelace, J. L., Fridland, G., Soong, Y., Fasolo, J., Wu, D., et al. (2001). In vivo pharmacokinetics of selective mu-opioid peptide agonists. Journal of Pharmacology and Experimental Therapeutics, 298, 57–61.PubMed

Szeto, H. H., Schiller, P. W., Zhao, K., & Luo, G. (2005). Fluorescent dyes alter intracellular targeting and function of cell-penetrating tetrapeptides. FASEB Journal, 19, 118–120.PubMed

Tabrizin, S. J., Cleeter, M. W., Xuereb, J., Taanman, J. W., Cooper, J. M., & Schapira, A. H. (1999). Biochemical abnormalities and excitotoxicity in Huntington’s disease brain. Annals of Neurology, 45, 25–32. doi:10.1002/1531–8249(199901)45:1<25::AID-ART6>3.0.CO;2-E

Taira, T., Saito, Y., Niki, T., Iguchi-Ariga, S. M., Takahashi, K., & Ariga, H. (2004). DJ–1 has a role in antioxidative stress to prevent cell death. EMBO Reports, 5, 213–218. doi:10.1038/sj.embor.7400074.PubMed

Takuma, K., Yao, J., Huang, J., Xu, H., Chen, X., Luddy, J., et al. (2005). ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB Journal, 19, 597–598.PubMed

Tamagno, E., Gugglielmotto, M., Argno, M., Borghi, R., Autelli, R., Giliberto, L., et al. (2008). Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. Journal of Neurochemistry, 104, 683–695.PubMed

Thies, E., & Mandelkow, E. M. (2007). Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. Journal of Neuroscience, 27, 2896–2907. doi:10.1523/JNEUROSCI.4674-06.2007.PubMed

Thomas, B & Beal, M. F. (2007). Parkinson’s disease. Human molecular genetics, 16(Spec No. 2), R183–R194.

Thomas, D. A., Stauffer, C., Zhao, K., Yang, H., Sharma, V. K., Szeto, H. H., et al. (2007). Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttransplantation function. Journal of the American Society of Nephrology, 18, 213–222. doi:10.1681/ASN.2006080825.PubMed

Tissenbaum, H. A., & Guarente, L. (2001). Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature, 410, 227–230. doi:10.1038/35065638.PubMed

Trifunovic, A., Wredenberg, A., Falkenberg, M., et al. (2004). Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature, 429, 417–423. doi:10.1038/nature02517.PubMed

Trimmer, P. A., Swerdlow, R. H., Park, J. K., Keeney, P., Bennet, J. P., Miller, S. W., et al. (2004). Abnormal mitochondrial morphology in sporadic Parkinson’s and Alzheimer’s disease cybrid cell lines. Experimental Neurology, 162, 37–50. doi:10.1006/exnr.2000.7333.

Trushina, E., Dyer, R. B., Badger, J. D., & 2nd., (2004). Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Molecular and Cellular Biology, 24, 8195–8209. doi:10.1128/MCB.24.18.8195-8209.2004.

Trushina, E., & McMurray, C. T. (2007). Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience, 145, 1233–1248. doi:10.1016/j.neuroscience.2006.10.056.PubMed

Valente, E. M., Abou-Sleiman, P. M., Caputo, V., et al. (2004). Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science, 304, 1158–1160. doi:10.1126/science.1096284.PubMed

Van Blerkom, J. (2008). Mitochondria as regulatory forces in oocytes, preimplantation embryos and stem cells. Reproductive Biomedicine Online, 16, 553–569.PubMedCrossRef

Van Raamsdonk, J. M., Warby, S. C., & Hayden, M. R. (2007). Selective degeneration in YAC mouse models of Huntington disease. Brain Research Bulletin, 72, 124–31. doi:10.1016/j.brainresbull.2006.10.018.PubMed

Van Remmen, H., Qi, W., Sabia, M., Freeman, G., Estlack, L., Yang, H., et al. (2004). Multiple deficiencies in antioxidant enzymes in mice result in a compound increase in sensitivity to oxidative stress. Free Radical Biology and Medicine, 36, 1625–1634. doi:10.1016/j.freeradbiomed.2004.03.016.PubMed

Vijayvergiya, C., Beal, M. F., Buck, J., & Manfredi, G. (2005). Mutant superoxide dismutase 1 forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice. Journal of Neuroscience, 25, 2463–2470. doi:10.1523/JNEUROSCI.4385-04.2005.PubMed

Vinogradov, A. D., & Grivennikova, V. G. (2005). Generation of superoxide-radical by the NADH:ubiquinone oxidoreductase of heart mitochondria. Biochemistry (Mosc), 70, 120–127.

Vonsattel, J. P., Myers, R. H., Stevens, T. J., Ferrante, R. J., Bird, E. D., & Richardson, E. P., Jr. (1985). Neuropathological classification of Huntington’s disease. Journal of Neuropathology and Experimental Neurology, 44, 559–577. doi:10.1097/00005072-198511000-00003.PubMed

Wallace, D. C. (1999). Mitochondrial diseases in man and mouse. Science, 283, 1482–1448. doi:10.1126/science.283.5407.1482.PubMed

Wallace, D. C. (2005a). A mitochondrial paradigm of metabolic & degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. Annual Review of Genetics, 39, 359–407. doi:10.1146/annurev.genet.39.110304.095751.PubMed

Wallace, D. C. (2005b). The mitochondrial genome in human adaptive radiation and disease: On the road to therapeutics and performance enhancement. Gene, 354, 169–180. doi:10.1016/j.gene.2005.05.001.PubMed

Wang, J., Ho, L., Qin, W., et al. (2005a). Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer’s disease. FASEB Journal, 19, 659–661. doi:10.1096/fj.04-2370com.PubMed

Wang, H. Q., Nakaya, Y., Du, Z., et al. (2005b). Interaction of presenilins with FKBP38 promotes apoptosis by reducing mitochondrial Bcl-2. Human Molecular Genetics, 14, 1889–1902. doi:10.1093/hmg/ddi195.PubMed

Watanabe, M., Dykes-Hoberg, M., Culotta, V. C., Price, D. L., Wong, P. C., & Rothstein, J. D. (2001). Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiology of Disease, 8, 933–941. doi:10.1006/nbdi.2001.0443.PubMed

West, A. B., Morre, D. J., Biskup, S., Bugayenko, A., Smith, W·W., Ross, C. A., Dawson, V. L., Dawson, T. M. (2005). Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proceedings of the National Academy of Sciences of the United States of America, 102, 16842–1687.

Weydt, P., Pineda, V. V., Torrence, A. E., et al. (2006). Thermoregulatory and metabolic defects in Huntington’s disease transgenic mice implicate PGC-1alpha in Huntington’s disease neurodegeneration. Cell Metabolism, 4, 349–362. doi:10.1016/j.cmet.2006.10.004.PubMed

Wilson, R. B. (2006). Iron dysregulation in Friedreich ataxia. Seminars in Pediatric Neurology, 3, 166–175. doi:10.1016/j.spen.2006.08.005.

Wong, P. C., Pardo, C. A., Borchelt, D. R., Lee, M. K., Copeland, N. G., Jenkins, N. A., et al. (1995). An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron, 14, 1105–1116. doi:10.1016/0896-6273(95)90259-7.PubMed

Wood, J. G., Rogina, B., Lavu, S., Howitz, K., Helfand, S. L., Tatar, M., et al. (2004). Sirtuin Ctivators mimic caloric restriction and delay ageing in metazoans. Nature, 430, 686–689. doi:10.1038/nature02789.PubMed

Yoon, Y. S., Yoon, D. S., Lim, I. K., et al. (2006). Formation of elongated giant mitochondria in DFO-induced cellular senescence: Involvement of enhanced fusion process through modulation of Fis1. Journal of Cellular Physiology, 209, 468–480. doi:10.1002/jcp. 20753.PubMed

Zhang, L., Shimoji, M., Thomas, B., Moore, D. J., Yu, S. W., Marupudi, N. I., Torp, R., Torgner, I. A., Ottersen, O. P., Dawso, T. M., & Dawson, V. L. (2005). Mitochondrial localization of the Parkinson's disease related protein DJ-1: Implications for pathogenesis. Human Molecular Genetics, 14, 2063–2073.

Zhao, K., Luo, G., Zhao, G. M., Schiller, P. W., & Szeto, H. H. (2003). Transcellular transport of a highly polar 3 + net charge opioid tetrapeptide. Journal of Pharmacology and Experimental Therapeutics, 304, 425–432. doi:10.1124/jpet.102.040147.PubMed

Zhao, G. M., Wu, D., Soong, Y., Shimoyama, M., Berezowska, I., Schiller, P. W., et al. (2002). Profound spinal tolerance after repeated exposure to a highly selective mu-opioid peptide agonist: Role of delta-opioid receptors. Journal of Pharmacology and Experimental Therapeutics, 302, 188–196. doi:10.1124/jpet.302.1.188.PubMed

Zhao, K., Zhao, G. M., Wu, D., Soong, Y., Birk, A. V., Schiller, P. W., et al. (2004). Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. Journal of Biological Chemistry, 279, 34682–34690. doi:10.1074/jbc.M402999200.PubMed

Zimprich, A., Biskup, S., Leitner, P., et al. (2004). Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 44, 601–607. doi:10.1016/j.neuron.2004.11.005.PubMed

Titel: Mitochondrial Medicine for Aging and Neurodegenerative Diseases
verfasst von: P. Hemachandra Reddy
Publikationsdatum: 01.12.2008
Verlag: Humana Press Inc
Erschienen in: NeuroMolecular Medicine / Ausgabe 4/2008
Print ISSN: 1535-1084
Elektronische ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-008-8044-z

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2008

Evaled Expression of ICAM-1 and Its Ligands in the Rat Spinal Cord Following Lipopolysaccharide Intraspinal Injection

Mutual Stimulation of Beta-Amyloid Fibrillogenesis by Clioquinol and Divalent Metals

Genetic Variation in the α7 Nicotinic Acetylcholine Receptor is Associated with Delusional Symptoms in Alzheimer’s Disease

Creatine and Its Potential Therapeutic Value for Targeting Cellular Energy Impairment in Neurodegenerative Diseases

Coupling Endoplasmic Reticulum Stress to the Cell Death Program in Dopaminergic Cells: Effect of Paraquat